HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $725,000 | +8.5% | 18,988 | +3.2% | 0.00% | 0.0% |
| Q2 2023 | $668,000 | -1.8% | 18,405 | +3.2% | 0.00% | 0.0% |
| Q1 2023 | $680,000 | -86.8% | 17,842 | -80.3% | 0.00% | -91.7% |
| Q4 2022 | $5,136,000 | +34.4% | 90,352 | -6.2% | 0.01% | +20.0% |
| Q3 2022 | $3,821,000 | +466.9% | 96,305 | +526.8% | 0.01% | +400.0% |
| Q2 2022 | $674,000 | +41.3% | 15,364 | +28.5% | 0.00% | +100.0% |
| Q1 2022 | $477,000 | +7.0% | 11,952 | +7.3% | 0.00% | 0.0% |
| Q4 2021 | $446,000 | +14.1% | 11,140 | +15.6% | 0.00% | 0.0% |
| Q3 2021 | $391,000 | -15.2% | 9,635 | -5.1% | 0.00% | 0.0% |
| Q2 2021 | $461,000 | +19.1% | 10,154 | +9.7% | 0.00% | 0.0% |
| Q1 2021 | $387,000 | +37.7% | 9,258 | +41.4% | 0.00% | 0.0% |
| Q4 2020 | $281,000 | -36.6% | 6,548 | -77.1% | 0.00% | -50.0% |
| Q3 2019 | $443,000 | -11.4% | 28,629 | -1.7% | 0.00% | -33.3% |
| Q2 2019 | $500,000 | +5.0% | 29,129 | -1.7% | 0.00% | 0.0% |
| Q1 2019 | $476,000 | +13.9% | 29,629 | +3.5% | 0.00% | 0.0% |
| Q4 2018 | $418,000 | -15.0% | 28,615 | +5.8% | 0.00% | -25.0% |
| Q3 2018 | $492,000 | +37.0% | 27,056 | +26.7% | 0.00% | +33.3% |
| Q2 2018 | $359,000 | -31.9% | 21,349 | -20.5% | 0.00% | -25.0% |
| Q1 2018 | $527,000 | +48.0% | 26,868 | +53.1% | 0.00% | +33.3% |
| Q4 2017 | $356,000 | -12.7% | 17,548 | -28.2% | 0.00% | 0.0% |
| Q3 2017 | $408,000 | -8.5% | 24,430 | -30.5% | 0.00% | -25.0% |
| Q2 2017 | $446,000 | +26.0% | 35,149 | +28.5% | 0.00% | +33.3% |
| Q1 2017 | $354,000 | -9.7% | 27,350 | -30.8% | 0.00% | -25.0% |
| Q4 2016 | $392,000 | -17.1% | 39,550 | +1.3% | 0.00% | -20.0% |
| Q3 2016 | $473,000 | +40.8% | 39,050 | 0.0% | 0.01% | +25.0% |
| Q2 2016 | $336,000 | +5.3% | 39,050 | +16.1% | 0.00% | +300.0% |
| Q1 2016 | $319,000 | -32.1% | 33,636 | +23.5% | 0.00% | -83.3% |
| Q4 2015 | $470,000 | +27.4% | 27,236 | -1.0% | 0.01% | +20.0% |
| Q3 2015 | $369,000 | -8.7% | 27,513 | +53.8% | 0.01% | -16.7% |
| Q2 2015 | $404,000 | -4.7% | 17,888 | -39.7% | 0.01% | 0.0% |
| Q1 2015 | $424,000 | +16.2% | 29,675 | -21.4% | 0.01% | 0.0% |
| Q4 2014 | $365,000 | +37.2% | 37,775 | +29.0% | 0.01% | +50.0% |
| Q3 2014 | $266,000 | -8.0% | 29,275 | 0.0% | 0.00% | -20.0% |
| Q2 2014 | $289,000 | -22.3% | 29,275 | 0.0% | 0.01% | -28.6% |
| Q1 2014 | $372,000 | -18.1% | 29,275 | -3.3% | 0.01% | -22.2% |
| Q4 2013 | $454,000 | +38.0% | 30,275 | +1.7% | 0.01% | +12.5% |
| Q3 2013 | $329,000 | +30.0% | 29,775 | -6.3% | 0.01% | +14.3% |
| Q2 2013 | $253,000 | – | 31,775 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |